SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?


To: former_pgs who wrote (411)11/2/2006 10:05:49 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 447
 
Thanks,

18% RR and 50% control rate isn't bad for A-T arm. It appears that there is some apoptotic effect from this combination (due to ...???, duration of response = ??), and effect is on metastatic as well primary tumor.

because both drug are available, MDs may try this combination before approval (but this will reduce pts trials enrollment rate).

Miljenko